Shares of Roche Holding AG (OTCMKTS:SNYNF) were up 0.8% during trading on Wednesday . The stock traded as high as $84.85 and last traded at $84.54, approximately 5,204 shares were traded during trading. A decline of 54% from the average daily volume of 11,216 shares. The stock had previously closed at $83.90.

Separately, Jefferies Financial Group reaffirmed a “buy” rating and set a $95.00 price target on shares of Roche in a research report on Wednesday, July 10th.


Sanofi provides therapeutic solutions worldwide. It offers Cerezyme and Cerdelga for Gaucher, Myozyme and Lumizyme for Pompe, Fabrazyme for Fabry, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio, an immunomodulatory and Lemtrada, a monoclonal antibody for multiple sclerosis. It also provides Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Eloctate and Alprolix to treat hemophilia in adults and children; and Cablivi to treat acquired thrombotic thrombocytopenic purpura in adults.

Read More: What is a Buy-Side Analyst?

Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with's FREE daily email newsletter.